Vitiligo
☆ AI Dermatology — Free Service
ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
Vitiligo ຂອງນິ້ວມືແມ່ນມີຄວາມຫຍຸ້ງຍາກໃນການປິ່ນປົວຫຼາຍກວ່າພື້ນທີ່ອື່ນໆ. ນອກເຫນືອຈາກການເປັນເຄື່ອງສໍາອາງ unsightly, vitiligo ແມ່ນປົກກະຕິແລະບໍ່ຕິດເຊື້ອ. ໃນການປິ່ນປົວຜິວຫນັງ, ການປິ່ນປົວທີ່ມີປະສິດທິພາບສູງທີ່ສຸດແມ່ນການປິ່ນປົວດ້ວຍການຖ່າຍຮູບຫຼືການປິ່ນປົວດ້ວຍ excimer 2‑3 ຄັ້ງຕໍ່ອາທິດ ຢ່າງນ້ອຍ 1 ປີ. ຖ້າທ່ານບໍ່ສາມາດໄປຮັບການປິ່ນປົວໄດ້ ເນື່ອງຈາກສະພາບການເງິນ ຫຼື ຍຸ້ງຢູ່, ທ່ານສາມາດລອງໃຊ້ອຸປະກອນບຳບັດຮູບຊົງທີ່ອະນຸຍາດໃຊ້ຢູ່ທີ່ບ້ານ.
ຜິວໜັງຕາ ອັກເສບ
Vitiligo ຢູ່ມື
relevance score : -100.0%
ReferencesVitiligo ແມ່ນພະຍາດຜິວໜັງທົ່ວໄປທີ່ເຮັດໃຫ້ເກີດຈຸດດ່າງດຳຂອງຜິວໜັງເນື່ອງຈາກການສູນເສຍເມັດສີmelanocytes. ການຄົ້ນຄວ້າທີ່ຜ່ານມາສະແດງໃຫ້ເຫັນວ່າມັນເປັນພະຍາດautoimmune. ໃນຂະນະທີ່ມັນມັກຈະຖືກເບິ່ງແບບວ່າເປັນບັນຫາເຄື່ອງສໍາອາງ, ມັນສາມາດສົ່ງຜົນກະທົບຕໍ່ສຸຂະພາບຈິດແລະຊີວິດປະຈໍາວັນໄດ້ເລິກເຊັ່ນ. ໃນປີ2011, ຜູ້ຊ່ຽວຊານໄດ້ຈັດປະເພດທີ່ເອີ້ນວ່າsegmental vitiligo ແຍກຕ່າງຈາກຄົນອື່ນ.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
ຄົນເຈັບ vitiligo ທີ່ມີທາງເລືອກການປິ່ນປົວຫຼາຍ ເຊັ່ນ glucocorticoids, phototherapy ແລະການສົ່ງພູມຕ້ານທານ. ຄົນເຈັບ vitiligo ອາດຈະຕ້ອງຫາວິທີບໍ່ໃຊ້ corticosteroids ສະເພາະ, ນອກຈາກນັ້ນຍັງມີຢາປະເພດ calcineurin topical, phototherapy ແລະຂັ້ນຕອນການປູກຖ່າຍ. ການຄົ້ນຄ້ວາກ່ອນໜ້າຂອງ vitiligo ໄດ້ຊ່ວຍໃຫ້ພັດທະນາການປິ່ນປົວເປັນຈຸດປະສົງ. ຕອນນີ້ JAK inhibitors ແມ່ນທາງເລືອກທີ່ດີທີ່ສຸດ, ສະເຫນີຄວາມທົນທານທີ່ດີ ແລະຜົນຜະລິດທີ່ແມ່ນປະໂຫຍດ, ແມ່ນວ່າຍັງມີຄວາມສ່ຽງຕໍ່ການກະຕຸ້ນການຕິດເຊື້ອ ແລະຜົນຂ້າງຄຽງຂອງລະບົບທົ່ວໄປທີ່ກ່ຽວຂ້ອງກັບອິມູນຊັບສັດອື່ນໆ (immunosuppressive). ການຄົ້ນຄ້ວາຕໍ່ເນື່ອງມີຈຸດປະສົງເພື່ອກໍານົດ cytokines ທີ່ສໍາຄັນກັບການພັດທະນາ vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). ການຂັດຂວາງ cytokines ເຫຼົ່ານີ້ໄດ້ສະແດງຜົນໃນການທົບທວນທາງການສັດແລະຜົນກະທົບຕໍ່ຄົນເຈັບບາງຄົນ. ນອກຈາກນັ້ນ, ການສຶກສາ miRNA‑based therapeutics ແລະ adoptive Treg cell therapy ກໍພັດທະນາຢູ່ຕໍ່ໜ້າ.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
ບໍ່ມີການປິ່ນປົວທີ່ຮູ້ຈັກສໍາລັບ vitiligo. ສໍາລັບຜູ້ທີ່ມີຜິວຫນັງອ່ອນ, ການກວດກາກັນແດດ ແລະການປັບສະພາບຜິວຫນັງແມ່ນທັງຫມົດທີ່ແນະນໍາ. ທາງເລືອກການປິ່ນປົວອື່ນໆ ອາດຈະປະກອບມີການໃຊ້ສະຕຣອິດ (steroid) ຫຼື phototherapy.
○ ການປິ່ນປົວ
#Phototherapy
#Excimer laser
#Tacrolimus ointment